These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22089931)

  • 1. PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in situ hybridization.
    Dumont SN; Lazar AJ; Bridge JA; Benjamin RS; Trent JC
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):213-20. PubMed ID: 22089931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
    Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
    Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
    Yasuda T; Perry KD; Nelson M; Bui MM; Nasir A; Goldschmidt R; Gnepp DR; Bridge JA
    Hum Pathol; 2009 Mar; 40(3):341-8. PubMed ID: 18973919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
    Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
    Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
    Kazanowska B; Reich A; Stegmaier S; Békássy AN; Leuschner I; Chybicka A; Koscielniak E
    Fetal Pediatr Pathol; 2007; 26(1):17-31. PubMed ID: 17613043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
    Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
    J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
    Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
    Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
    Kelly KM; Womer RB; Sorensen PH; Xiong QB; Barr FG
    J Clin Oncol; 1997 May; 15(5):1831-6. PubMed ID: 9164192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.
    Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Alveolar rhabdomyosarcoma: Two fusion-negative cases lacking PAX3-FOXO1 and PAX7-FOXO1].
    Mestre-Alagarda C; Gómez-Mateo MC; Berenguer-Romero MD; Syonghyun NC; Nieto G; Navarro-Fos S
    Rev Esp Patol; 2022; 55(1):57-62. PubMed ID: 34980443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification of rhabdomyosarcoma and its molecular basis.
    Parham DM; Barr FG
    Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
    Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
    Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
    Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
    Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of FOXO1 (FKHR) gene break-apart by fluorescence in situ hybridization in formalin-fixed, paraffin-embedded alveolar rhabdomyosarcomas and its clinicopathologic correlation.
    Mehra S; de la Roza G; Tull J; Shrimpton A; Valente A; Zhang S
    Diagn Mol Pathol; 2008 Mar; 17(1):14-20. PubMed ID: 18303411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative utility of fluorescence in situ hybridization and reverse transcription-polymerase chain reaction in the diagnosis of alveolar rhabdomyosarcoma.
    Thway K; Wang J; Wren D; Dainton M; Gonzalez D; Swansbury J; Fisher C
    Virchows Arch; 2015 Aug; 467(2):217-24. PubMed ID: 25912319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
    Heerema-McKenney A; Wijnaendts LC; Pulliam JF; Lopez-Terrada D; McKenney JK; Zhu S; Montgomery K; Mitchell J; Marinelli RJ; Hart AA; van de Rijn M; Linn SC
    Am J Surg Pathol; 2008 Oct; 32(10):1513-22. PubMed ID: 18708938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.